Compare BDSX & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDSX | AGEN |
|---|---|---|
| Founded | 2005 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.3M | 147.4M |
| IPO Year | 2020 | 1999 |
| Metric | BDSX | AGEN |
|---|---|---|
| Price | $15.49 | $2.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $32.50 | $14.50 |
| AVG Volume (30 Days) | 36.3K | ★ 581.5K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 1.02 |
| Revenue | ★ $88,499,000.00 | $42,877,086.00 |
| Revenue This Year | $25.26 | $107.63 |
| Revenue Next Year | $19.15 | N/A |
| P/E Ratio | ★ N/A | $2.97 |
| Revenue Growth | 24.08 | ★ 89.95 |
| 52 Week Low | $0.26 | $2.71 |
| 52 Week High | $20.21 | $7.34 |
| Indicator | BDSX | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 52.46 | 38.63 |
| Support Level | $14.61 | $2.93 |
| Resistance Level | $16.66 | $3.15 |
| Average True Range (ATR) | 0.94 | 0.22 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 24.61 | 13.43 |
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.